News
🇺🇸 AmericasLatest pharmaceutical news, drug approvals, and FDA regulatory updates
Latest News
Theradaptive Receives FDA Approval for Pivotal Phase 3 Trial of OsteoAdapt SP in Spinal Fusion
Theradaptive advances OsteoAdapt SP bone regeneration therapy to pivotal Phase 3 OASIS trial for spinal fusion after FDA approval milestone.
Pharma Partnering US: $77.3B Licensing Deals in Q1 2026
US biopharma licensing reached $77.3 billion in Q1 2026, with M&A totaling $15.6 billion across 19 deals. Strategic partnering increasingly prioritizes data-driven decisions, AI integration, and niche modalities like ADCs and peptides.
Fierce Biotech Week 2026: AI & Oncology Pipeline Preview
Fierce Biotech Week 2026 is scheduled for May 12-14 in Everett, MA. The conference will likely cover key trends in drug development, with potential discussions on artificial intelligence (AI) applications and oncology pipeline updates.
IPEC Excipient World Biologics Summit 2026: Preview
The IPEC Excipient World Biologics Summit, a key event for professionals in the pharmaceutical and biologics industries, will take place May 4-6, 2026, in Nashville, TN. This summit focuses on the critical role of excipients in biologics manufacturing.
Teva Acquires Emalex Biosciences for $700M to Gain First-in-Class Tourette Syndrome Drug Ecopipam
Teva's $700M acquisition of Emalex adds NDA-ready ecopipam, a first-in-class dopamine D1 antagonist for pediatric Tourette syndrome with FDA Fast Track status.
Purespring Therapeutics Publishes Study on NPHS2 Genetic Variants Driving Adult-Onset FSGS in US and UK Populations
Purespring Therapeutics reveals 77% of US adult-onset FSGS cases involve NPHS2 compound heterozygosity, with A284V variant prevalent in mixed-ancestry populations.
Viking Therapeutics VK2735 Phase 3 Obesity Trials Fully Enrolled as Company Reports Q1 2026 Results
Viking Therapeutics advances VK2735 obesity treatment with fully enrolled Phase 3 trials and $603M cash position, oral formulation trial expected Q4 2026.
Relay Therapeutics Q1 2026 Earnings: Zovegalisib PI3Kα Inhibitor Updates Expected May 5
Relay Therapeutics announces Q1 2026 financial results May 5, featuring updates on zovegalisib, the first pan-mutant selective PI3Kα inhibitor for cancer treatment.
Neurocrine Biosciences INGREZZA Shows Clinically Meaningful Improvement in Tardive Dyskinesia Study
New research establishes clinically meaningful improvement threshold for INGREZZA (valbenazine) in tardive dyskinesia patients using TDIS scale.
Novo Nordisk's Denecimig Shows Significant Bleeding Reduction in Hemophilia A Phase 3 Trial Published in NEJM
Denecimig (Mim8) significantly reduced annualized bleeding rates in hemophilia A patients regardless of inhibitor status in pivotal FRONTIER2 study.
Addex Therapeutics GABAB PAM Shows Promise for IPF-Related Chronic Cough in Preclinical Study
Addex Therapeutics reports positive preclinical data for its GABAB PAM candidate treating chronic cough in idiopathic pulmonary fibrosis patients.
IgA Nephropathy Market to Reach New Heights by 2036 as Novartis Zigakibart and Novel Immunotherapies Drive Growth
IgA nephropathy market expansion driven by Novartis Zigakibart, Roche Sefaxersen, and emerging immunotherapies through 2036 with improved patient outcomes.
Perimeter Medical's Claire OCT+AI Receives FDA Approval for Breast Cancer Surgery Margin Assessment
Perimeter Medical's Claire OCT+AI becomes first FDA-approved AI-enabled device for real-time breast cancer margin assessment during surgery at ASBrS 2026.
Regeneron Q1 2026 Earnings: Dupixent Sales Surge 33% to $4.9B, EYLEA HD Shows Strong Growth
Regeneron reports 19% revenue growth to $3.6B in Q1 2026, driven by Dupixent's 33% sales increase to $4.9B and EYLEA HD's 52% growth to $468M.
Sprout Pharmaceuticals Addyi (Flibanserin) Maker Named Top 10 Most Influential Health Company by TIME 2026
Sprout Pharmaceuticals, maker of Addyi (flibanserin), joins TIME's 10 most influential health companies of 2026 following FDA approval expansion and growth.
Clinical Outsourcing: Key Takeaways from 2026 Trends
Clinical outsourcing markets are experiencing robust 2026 growth, with drug discovery reaching USD 5.04 billion and medical writing at USD 5.70 billion, driven by AI-enabled platforms, CRO consolidation, and FDA real-time trial monitoring innovations.
Clinical Outsourcing Trends 2026: Key Takeaways for Pharma
The clinical outsourcing market in 2026 is characterized by significant growth across medical writing (USD 5.70 billion), drug discovery outsourcing (USD 5.04 billion), and strategic CRO consolidation, with AGC Biologics recognized for regulatory excellence and Asia-Pacific emerging as a key growth region.
IEEE CoG 2026: Industry Day and Game Dev Tutorials Preview
IEEE CoG 2026, the 4th Annual Conference on Games, will convene September 1–4, 2026, in Madrid, Spain, featuring free Industry Day programming, specialized tutorials on game development and player analytics, and peer-reviewed research presentations.
Pharma Partnering US: Biotech Dealmaking Heats Up
Pharma Partnering US continues to drive biotech dealmaking with emerging trends in milestone-based payments, equity co-investment, and manufacturing partnerships. Early-stage biotech companies are increasingly prioritizing clinical validation and regulatory clarity to attract strategic partners.
Clinical Outsourcing Group: Key Takeaways for Pharma
The Clinical Outsourcing Group convened pharmaceutical industry stakeholders to examine evolving trends in clinical trial outsourcing, including decentralized trial models, real-world evidence integration, and emerging market expansion. Key discussions highlighted how CROs are reshaping drug development timelines and addressing talent constraints through digital innovation.